Retatrutide (10mg)
Retatrutide (LY3437943) — 10mg | Research Grade | Australia
Retatrutide is a next-generation synthetic triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. It represents one of the most actively investigated compounds in current metabolic research, with a growing body of peer-reviewed preclinical and clinical literature examining its receptor binding properties and downstream biological activity in research settings. Buy Retatrutide in Australia from Austides — research-grade, third-party tested, domestically dispatched with cold-chain integrity.
Research Applications
Examined in research settings for its effects on body composition parameters via triple receptor agonism in preclinical models
Studied for its influence on insulin sensitivity markers and glycaemic regulation mechanisms in animal models
Investigated for centrally mediated appetite modulation pathways in preclinical research contexts
Subject of research into cardiovascular and metabolic biomarker outcomes in preclinical models
Under active investigation for its effects on hepatic lipid accumulation in animal research models
Product Specifications
Also Known As | LY3437943 |
Classification | GIP / GLP-1 / Glucagon Triple Agonist |
Molecular Weight | ~4.8 kDa |
Form | Lyophilised powder |
Purity | ≥99% (HPLC verified) |
Storage | Store at -20°C, away from light. Stable 24 months unopened. |
Austides Standard
All Austides peptides are third-party tested for purity and potency. Domestically dispatched from Australia with discrete, secure packaging and cold-chain integrity maintained throughout.
For research purposes only. Not for human consumption, therapeutic use, or self-administration. This product is not approved by the TGA for any therapeutic application.
){kind=link}